Study of calaspargase pegol on blood clotting in pediatric leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 21.5 years old
- Diagnosed with acute lymphoblastic leukemia or lymphoma
- Will be receiving calaspargase pegol (Cal-PEG) as part of treatment
- No known bleeding or clotting disorders
- No blood thinners taken within 48 hours before the study blood draw
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how long the chemotherapy medicine calaspargase stays active in the body. It may help doctors understand how to dose this medicine better for future patients.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
This trial looks at how a medicine called asparaginase affects blood clotting in children treated for acute lymphoblastic leukaemia (a type of blood cancer). It may help doctors better manage bleeding or clot risks during treatment.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This study looks at how a common chemotherapy drug called asparaginase affects people in real life. It aims to understand side effects better so doctors can improve care for patients with leukemia or lymphoma.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Hear when a new Childhood Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.